Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

In Brief: Unigene

Executive Summary

Unigene: Signs letter of intent with Warner-Lambert for worldwide rights to oral calcitonin for treatment of osteoporosis. Under the agreement, Warner-Lambert will assume responsibility for development and marketing of the product and Unigene will provide bulk active raw material. If the product development is successful, Warner-Lambert will make up-front and milestone payments of $50 mil., pay royalties, and purchase Unigene stock. The companies plan to execute a definitive agreement in mid-July...
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS030478

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel